Table 2 Targeted therapy by histotypes
From: The off-label use of targeted therapies in sarcomas: the OUTC’S program
Targeted therapy | N | % | Histotype 1 | n (%) | Histotype 2 | n (%) | Histotype 3 | n (%) | Histotype 4 | n (%) | Histotype 5 | n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sorafenib (1) | 125 | 45 | GIST | 31 (25) | LMS | 22 (18) | AS | 14 (11) | Uterine LMS | 8 (6) | Liposarcoma | 8 (6) |
Suntinib (2) | 67 | 24 | LMS | 9 (13) | Ewing | 8 (12) | SS | 8 (12) | Unclassified S | 8 (12) | Uterine LMS | 4 (6) |
Imatinib | 23 | 8 | Chordoma | 8 (35) | AF | 4 (17) | DFSP | 4 (17) | Epithelioid S | 2 (9) | ─ | ─ |
Sirolimus-cyclophosphamide | 18 | 6 | OsteoS | 8 (44) | ChondroS | 5 (27) | AS/chordoma/lipoS/Ewing/SFT | 1 each (6) | ─ | ─ | ─ | ─ |
Everolimus (3) | 10 | 4 | GIST | 3 (30) | LMS | 3(30) | KS/MPNST/SS | 1 each (10) | Other | 1(10) | ─ | ─ |
Bevacizumab (4) | 9 | 3 | Other | 5 (56) | MFST | 2 (22) | AS | 1 (11) | Epithelioid S | 1 (11) | ─ | ─ |
Sirolimus alone | 5 | 2 | OsteoS | 2 (40) | PEComa | 1 (20) | other | 1 (20) | ─ | ─ | ─ | ─ |